Toxys

What Toxys does

Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing.

Name

Toxys

Legal name

Toxys B.V.

Website

http://toxys.com/

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Toxys is a Dutch biotech company.

Ownership category

akta.pro rank

Product category

In Vitro Toxicology Testing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

Keywords

• In vitro toxicology testing
• Genotoxicity assays
• Developmental toxicology
• Mechanism-based screening
• Non-animal safety testing

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Toxys provides contracted laboratory testing services using its proprietary in vitro assays. Clients submit compounds for genotoxicity, developmental toxicity, or investigative toxicology testing and receive detailed reports including cytotoxicity data, genotoxicity assessments, and benchmark dose (BMD) analysis. Services are offered on a project-by-project basis with quotes provided based on study scope.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Toxys is a Dutch contract research organization that delivers mechanism-based in vitro toxicology testing services for chemical, pharmaceutical, cosmetics, food/feed, and nanomaterial safety assessment. Its offering centers on proprietary reporter-cell and hiPSC-based assays (ToxTracker Suite, ReproTracker, ToxProfiler, MutaTracker, MitoToxScreen) and complementary GLP/non-GLP assays (comet, Hprt, clonogenic, Alamar Blue), provided as study-based testing services to industrial R&D and regulatory safety teams.

Product overview

Toxys is a Dutch biotech company offering a comprehensive portfolio of in vitro toxicity screening solutions organized into four service categories: Genetic Toxicology, Developmental Toxicology, Investigative Toxicology, and Cytotoxicity. The core platform is the ToxTracker Suite, which contains multiple mechanism-based genotoxicity assays (ToxTracker, ToxTracker ACE, ToxTracker AO, ToxTracker EMP, TubulinTracker) that can discriminate between DNA damage, oxidative stress, and protein damage mechanisms. The flagship ReproTracker assay uses human induced pluripotent stem cells (hiPSCs) for developmental toxicity assessment. Additional offerings include ToxProfiler/ToxProfiler MAX for investigative toxicology and standard cytotoxicity assays. The assays are designed to rapidly identify hazardous and carcinogenic properties of novel compounds during early drug development phases, contributing to reduced animal testing.

Differentiator

Problem solved

Functional benefit

Brands

• ToxTracker Suite: A collection of in vitro genotoxicity assays including ToxTracker, ToxTracker ACE, TubulinTracker, ToxTracker AO, and ToxTracker EMP that reliably identify genotoxic compounds and provide detailed insight into their mode-of-action.
• ToxTracker
• ReproTracker
• MutaTracker
• ToxProfiler
• ToxTracker Academy

Products and services

• ToxTracker Suite Mechanism-based in vitro genotoxicity assay suite using GFP reporter cell lines to detect DNA damage, oxidative stress, protein damage, and microtubule disruption in a single test, enabling discrimination between aneugens, clastogens, and other modes of action. Used by pharmaceutical, chemical, cosmetics, food, and nanomaterial safety teams for non-animal genotoxicity assessment.
• ReproTracker Developmental and reproductive toxicity testing service using human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and neural cell models to detect human-relevant developmental and cardiotoxicity hazards without animal use. Targeted at cosmetics, pharmaceutical, and chemical safety programs needing human-relevant developmental toxicity data.
• ToxProfiler Investigative toxicology service providing targeted molecular biomarker profiling using qPCR and protein arrays to characterize the biological pathways activated by compounds of interest. Used for mechanism-of-action studies and follow-up of positive in vitro toxicology findings.
• ToxProfiler MAX Extended investigative toxicology service delivering a broader panel of molecular biomarkers (qPCR and protein arrays) than standard ToxProfiler, enabling more comprehensive pathway-level mechanistic profiling of compounds.
• MutaTracker Genetic toxicology service for the detection and quantification of mutations in mammalian cells using a reporter gene readout, supporting mutagenicity assessment of chemicals and pharmaceuticals.
• MitoToxScreen Mitochondrial toxicity screening service assessing mitochondrial membrane potential, respiration, and related endpoints to identify compounds that impair mitochondrial function, relevant for drug, chemical, and nanomaterial safety assessment.
• DNA Repair-Profiler Genetic toxicology service profiling cellular DNA repair pathway activity to characterize how cells respond to genotoxic insult, supporting mechanistic interpretation of DNA damage findings.
• In vitro comet assay Single-cell gel electrophoresis (comet) assay service for detection of DNA strand breaks in vitro, delivered as part of Toxys's genetic toxicology testing portfolio for regulatory and investigative purposes.
• Hprt mutation assay In vitro mammalian-cell gene mutation assay at the Hprt locus, used to assess mutagenic potential of test substances as part of regulatory genetic toxicology testing packages.
• Clonogenic survival assay In vitro cytotoxicity assay service measuring clonogenic survival of cells following compound exposure, used to assess cytostatic and cytotoxic effects in non-clinical safety studies.
• Alamar Blue assay In vitro cytotoxicity assay service using Alamar Blue (resazurin reduction) to measure cell viability and metabolic activity following compound exposure, used as a general cytotoxicity screen.

Quantifiable outcome

• ToxTracker identifies in vivo genotoxicants with ~90% accuracy while reporting on oxidative and ER stressors that induce misleading positive test results in vitro
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• Institute for In Vitro Sciences (IIVS)coreStrategic or Co-development Partner · 17 July 2026Expanded strategic partnership to advance adoption of New Approach Methodologies (NAMs) in genetic toxicology. IIVS is a non-profit organization focused on advancing in vitro science. The partnership expansion aims to accelerate industry and regulatory acceptance of innovative in vitro methods for chemical safety assessment.
• Korean Institute of Toxicology (KIT)strategicStrategic or Co-development Partner · 24 March 2026Memorandum of Understanding signed at SOT 2026 Annual Meeting to advance collaboration in genetic toxicology. KIT is a Korean government research institute focused on toxicology. The MoU establishes a framework for joint development and knowledge sharing in the genetic toxicology field.
• Charles River LaboratoriescoreStrategic or Co-development Partner · 8 October 2025Collaboration to offer Charles River's clients access to ReproTracker for developmental toxicity testing. Charles River's Alternative Methods Advancement Project (AMAP) reinforces commitment to incorporating NAMs. This partnership provides Charles River's extensive DART client base access to Toxys's innovative in vitro developmental toxicity assay, complementing Charles River's traditional DART offerings.
• UnilevercoreStrategic or Co-development Partner · 14 August 2025Collaborative research on developmental and reproductive toxicity (DART) using NAMs. Unilever and Toxys scientists published on evaluation of a bioactivity and exposure-based NAM toolbox for NGRA frameworks. Joint development of ReproTracker for exposure-led in vitro developmental toxicity testing.
• HoneywellstrategicStrategic or Co-development Partner · 13 February 2025Collaboration on PFAS research published in Toxicology Letters. Utilized ToxProfiler and ReproTracker to assess toxicological mode-of-action and developmental toxicity of different PFAS compounds with varying carbon chain lengths.
• Health Canada and University of SwanseastrategicStrategic or Co-development Partner · 23 May 2018Collaboration to implement quantitative analysis (PROAST) of ToxTracker results for human risk assessment. Aimed at implementing point-of-departure metrics for in vitro genetic toxicity dose-response data.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Largest preclinical CRO globally with end-to-end genetic toxicology and DART service offerings; Toxys' direct distribution partner for ReproTracker. Both compete and partner in the in vitro toxicology services market.
• BioReliance (Merck/Sigma-Aldrich): Commercial testing services arm of Merck KGaA offering genetic toxicology, virology, and biosafety testing using in vitro assays. Directly comparable contract genetic toxicology laboratory.
• Eurofins Scientific: Global testing laboratory network with strong genetic toxicology and REACH testing offerings. Competes for the same pharma/chemical client testing budgets.
• Labcorp Drug Development (Covance): Major clinical and preclinical CRO with comprehensive in vitro toxicology and DART service portfolios serving global pharma clients.

Direct peers

• Cyprotex (Evotec): Subsidiary of Evotec providing in vitro ADME and mechanistic toxicology services for pharma and chemical clients. Closest comparable for mechanism-based toxicology screening CRO business.
• Stemina Biomarker Discovery: US-based developer of stem cell-based developmental toxicity assays (devTOX). Closest peer in hiPSC-based developmental toxicology testing services.
• Institute for In Vitro Sciences (IIVS): Non-profit organization advancing in vitro science including genetic toxicology assay protocols. Toxys' expanded strategic partner and participant in NAM advocacy/training.
• Environmental Health Sciences (EHS) — Genetic Toxicology Testing: Independent GLP-compliant genetic toxicology and in vitro toxicology contract laboratory with comparable GLP in vitro assay menu (Ames, micronucleus, comet, HPRT).
• GenoSafe: French CRO specializing in genetic toxicology and biotechnology-based testing services, including gene therapy safety assessment. Mid-sized competitor in the European genetic toxicology market.

Emerging players

• Cellaria Biosciences: Emerging player offering cell-based assay development and in vitro toxicology services using reporter technologies, partially overlapping with Toxys' mechanism-based assay approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCZ1
• LinkedInlinkedin.com/company/toxys-bv
• Xx.com/toxys_bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Toxys